Omalizumab in children with severe allergic disease: a case series

Giuseppe Crisafulli, Lucia Caminiti, Fernanda Chiera, Stefania Arasi, Giuseppina Salzano, Ilenia Panasiti, Andrea Barbalace, Giovanni Battista Pajno

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy.

METHODS: Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol.

RESULTS: Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies.

CONCLUSIONS: Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.

Original languageEnglish
Pages (from-to)13
JournalItalian Journal of Pediatrics
Volume45
Issue number1
DOIs
Publication statusPublished - Jan 14 2019

Fingerprint

Food Hypersensitivity
Asthma
Immunotherapy
Eosinophilic Esophagitis
Medical Economics
Nomograms
Emergency Treatment
Urticaria
Anaphylaxis
Standard of Care
Omalizumab
Allergens
Therapeutics
Public Health
Monoclonal Antibodies
Clinical Trials

Cite this

Crisafulli, G., Caminiti, L., Chiera, F., Arasi, S., Salzano, G., Panasiti, I., ... Pajno, G. B. (2019). Omalizumab in children with severe allergic disease: a case series. Italian Journal of Pediatrics, 45(1), 13. https://doi.org/10.1186/s13052-019-0602-5

Omalizumab in children with severe allergic disease : a case series. / Crisafulli, Giuseppe; Caminiti, Lucia; Chiera, Fernanda; Arasi, Stefania; Salzano, Giuseppina; Panasiti, Ilenia; Barbalace, Andrea; Pajno, Giovanni Battista.

In: Italian Journal of Pediatrics, Vol. 45, No. 1, 14.01.2019, p. 13.

Research output: Contribution to journalArticle

Crisafulli, G, Caminiti, L, Chiera, F, Arasi, S, Salzano, G, Panasiti, I, Barbalace, A & Pajno, GB 2019, 'Omalizumab in children with severe allergic disease: a case series', Italian Journal of Pediatrics, vol. 45, no. 1, pp. 13. https://doi.org/10.1186/s13052-019-0602-5
Crisafulli, Giuseppe ; Caminiti, Lucia ; Chiera, Fernanda ; Arasi, Stefania ; Salzano, Giuseppina ; Panasiti, Ilenia ; Barbalace, Andrea ; Pajno, Giovanni Battista. / Omalizumab in children with severe allergic disease : a case series. In: Italian Journal of Pediatrics. 2019 ; Vol. 45, No. 1. pp. 13.
@article{e9e6abd6b740464aa4d730d776c5a2e3,
title = "Omalizumab in children with severe allergic disease: a case series",
abstract = "BACKGROUND: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy.METHODS: Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol.RESULTS: Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies.CONCLUSIONS: Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.",
author = "Giuseppe Crisafulli and Lucia Caminiti and Fernanda Chiera and Stefania Arasi and Giuseppina Salzano and Ilenia Panasiti and Andrea Barbalace and Pajno, {Giovanni Battista}",
year = "2019",
month = "1",
day = "14",
doi = "10.1186/s13052-019-0602-5",
language = "English",
volume = "45",
pages = "13",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Omalizumab in children with severe allergic disease

T2 - a case series

AU - Crisafulli, Giuseppe

AU - Caminiti, Lucia

AU - Chiera, Fernanda

AU - Arasi, Stefania

AU - Salzano, Giuseppina

AU - Panasiti, Ilenia

AU - Barbalace, Andrea

AU - Pajno, Giovanni Battista

PY - 2019/1/14

Y1 - 2019/1/14

N2 - BACKGROUND: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy.METHODS: Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol.RESULTS: Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies.CONCLUSIONS: Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.

AB - BACKGROUND: Currently, severe allergic asthma and food allergy in children represent an important public health problem with medical, psychosocial and economic impacts. Omalizumab is a humanized monoclonal anti-IgE antibody, approved for refractory allergic asthma and chronic urticaria. It has been widely used in clinical practice as add-on therapy in patients with severe uncontrolled allergic asthma. In recent years there has seen the emergence of an allergic epidemic with increasing food allergy, which represents the main cause of anaphylaxis in children. The standard of care for food allergy is strictly dietary allergen avoidance and emergency treatment, but recent clinical trials have suggested that omalizumab may have a role to play as an adjuvant to oral immunotherapy (OIT). We present a case series of patients treated at our institution with omalizumab for severe allergic asthma and food allergy.METHODS: Patients received omalizumab according to a standard reference nomogram after failing standard therapies. In children with comorbid severe food allergy, omalizumab was administered in conjunction with an oral immunotherapy protocol.RESULTS: Omalizumab was effective in controlling symptoms of allergic asthma, allergic rhinitis and rhinosinusitis, but not eosinophilic esophagitis, while aiding successful oral desensitization of comorbid severe food allergies.CONCLUSIONS: Omalizumab appears to be an excellent therapeutic option in children with inadequately controlled severe allergic asthma, allergic rhinitis and rhinosinusitis, with or without food allergy.

U2 - 10.1186/s13052-019-0602-5

DO - 10.1186/s13052-019-0602-5

M3 - Article

C2 - 30642367

VL - 45

SP - 13

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 1

ER -